Clinical Trial Update: Niacin on Immune Activation : a Proof-of-concept Study [Phase 2]

View source ↗

Summary

Phase 2 proof-of-concept trial evaluating niacin for immune activation in people with HIV; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Infection

Drugs mentioned

• Niacin (nicotinic acid)

Snippet

Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre | Conditions: HIV | Phase 2 | Status: COMPLETED